• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Faculty of Medicine
  • Department of Clinical Science
  • Department of Clinical Science
  • View Item
  •   Home
  • Faculty of Medicine
  • Department of Clinical Science
  • Department of Clinical Science
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Tetradecylthioacetic Acid Increases Hepatic Mitochondrial b-Oxidation and Alters Fatty Acid Composition in a Mouse Model of Chronic Inflammation

Burri, Lena; Bjørndal, Bodil; Wergedahl, Hege; Berge, Kjetil; Bohov, Pavol; Svardal, Asbjørn; Berge, Rolf Kristian
Peer reviewed, Journal article
Published version
Thumbnail
View/Open
Published version (471.7Kb)
URI
https://hdl.handle.net/1956/5213
Date
2011-04-09
Metadata
Show full item record
Collections
  • Department of Clinical Science [1695]
Original version
https://doi.org/10.1007/s11745-011-3536-2
Abstract
The administration of tetradecylthioacetic acid (TTA), a hypolipidemic and anti-inflammatory modified bioactive fatty acid, has in several experiments based on high fat diets been shown to improve lipid transport and utilization. It was suggested that increased mitochondrial and peroxisomal fatty acid oxidation in the liver of Wistar rats results in reduced plasma triacylglycerol (TAG) levels. Here we assessed the potential of TTA to prevent tumor necrosis factor (TNF) a-induced lipid modifications in human TNFa (hTNFa) transgenic mice. These mice are characterized by reduced b-oxidation and changed fatty acid composition in the liver. The effect of dietary treatment with TTA on persistent, low-grade hTNFa overexpression in mice showed a beneficial effect through decreasing TAG plasma concentrations and positively affecting saturated and monounsaturated fatty acid proportions in the liver, leading to an increased anti-inflammatory fatty acid index in this group. We also observed an increase of mitochondrial b-oxidation in the livers of TTA treated mice. Concomitantly, there were enhanced plasma levels of carnitine, acetyl carnitine, propionyl carnitine, and octanoyl carnitine, no changed levels in trimethyllysine and palmitoyl carnitine, and a decreased level of the precursor for carnitine, called c-butyrobetaine. Nevertheless, TTA administration led to increased hepatic TAG levels that warrant further investigations to ascertain that TTA may be a promising candidate for use in the amelioration of inflammatory disorders characterized by changed lipid metabolism due to raised TNFa levels.
Publisher
Springer
Copyright
©The Author(s) 2011

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit